Cite
MLA Citation
R Morlock et al.. “658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA).” Annals of oncology, vol. 29, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100095323343.0x00003a